Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
72.71
+0.19 (0.26%)
Oct 27, 2025, 2:13 PM EDT - Market open
Corcept Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts that cover Corcept Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $139, which forecasts a 91.17% increase in the stock price over the next year. The lowest target is $121 and the highest is $150.
Price Target: $139 (+91.17%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Corcept Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $145 | Strong Buy | Reiterates | $145 | +99.42% | Oct 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $145 | Strong Buy | Reiterates | $145 | +99.42% | Oct 10, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $140 | Strong Buy | Maintains | $140 | +92.55% | Sep 25, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $137 → $140 | Strong Buy | Maintains | $137 → $140 | +92.55% | Sep 10, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $142 → $137 | Strong Buy | Maintains | $142 → $137 | +88.42% | Aug 1, 2025 |
Financial Forecast
Revenue This Year
869.77M
from 675.04M
Increased by 28.85%
Revenue Next Year
1.17B
from 869.77M
Increased by 34.98%
EPS This Year
1.02
from 1.23
Decreased by -17.28%
EPS Next Year
2.01
from 1.02
Increased by 97.74%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 918.8M | 1.5B | |||
| Avg | 869.8M | 1.2B | |||
| Low | 807.5M | 994.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 36.1% | 67.6% | |||
| Avg | 28.8% | 35.0% | |||
| Low | 19.6% | 14.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.20 | 3.35 | |||
| Avg | 1.02 | 2.01 | |||
| Low | 0.80 | 0.75 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.7% | 229.2% | |||
| Avg | -17.3% | 97.7% | |||
| Low | -34.7% | -25.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.